indomethacin has been researched along with Bronchopulmonary Dysplasia in 53 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Bronchopulmonary Dysplasia: A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the association between prophylactic indomethacin and bronchopulmonary dysplasia (BPD) in a recent, large cohort of extremely preterm infants." | 7.85 | Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants. ( Carper, B; Dysart, KC; Gantz, MG; Higgins, RD; Jensen, EA; Keszler, M; Laughon, MM; Poindexter, BB; Schmidt, B; Stoll, BJ; Walsh, MC, 2017) |
| "To determine the risk of bronchopulmonary dysplasia (BPD) in subgroups of infants with and without patent ductus arteriosus (PDA) who were randomized to indomethacin prophylaxis or placebo, and to examine whether adverse drug effects on edema formation and oxygenation may explain why indomethacin prophylaxis does not reduce BPD." | 7.73 | Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). ( Davis, P; Fanaroff, A; Kirpalani, HM; Nwaesei, C; Roberts, RS; Schmidt, B; Vincer, M, 2006) |
| "Eighty pregnant women threatened with preterm labor between 24 and 34 weeks of gestation were enrolled in the study." | 6.67 | Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterm labor. ( Eronen, M; Hallman, M; Kurki, T; Pesonen, E; Teramo, K; Ylikorkala, O, 1994) |
| "Expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks' postmenstrual age." | 5.69 | Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. ( Avino, D; de Baat, T; De Bisschop, B; de Boode, WP; de Vries, WB; Derriks, F; Dijk, PH; Dijkman, KP; Donders, R; Henriksen, TB; Hocq, C; Hundscheid, T; Kooi, EMW; Kroon, AA; Kyng, KJ; Meeus, M; Mulder, AL; Mulder-de Tollenaer, SM; Nuytemans, DHGM; Onland, W; van Kaam, AH; Van Overmeire, B; Vijlbrief, DC; Villamor, E; Visser, R; Zecic, A, 2023) |
| " We used the GRADE approach to assess the certainty of evidence for the following outcomes: failure of PDA closure within one week of administration of the first dose of indomethacin; bronchopulmonary dysplasia (BPD) at 28 days' postnatal age and at 36 weeks' postmenstrual age; proportion of infants requiring surgical ligation or transcatheter occlusion; all-cause neonatal mortality; necrotizing enterocolitis (NEC) (≥ Bell stage 2); and mucocutaneous or gastrointestinal bleeding." | 5.12 | Indomethacin for symptomatic patent ductus arteriosus in preterm infants. ( Evans, P; Flyer, JN; Mitra, S; O'Reilly, D; Soll, R, 2021) |
| " Early indomethacin was associated with a lower risk of patent ductus arteriosus and bronchopulmonary dysplasia and a higher risk of spontaneous intestinal perforation." | 4.12 | Model for severe intracranial hemorrhage and role of early indomethacin in extreme preterm infants. ( Ambalavanan, N; Bell, EF; Carlo, WA; Chawla, S; Chowdhury, D; Das, A; Gantz, M; Harmon, HM; Laptook, AR; Natarajan, G; Shankaran, S; Tapia, JL, 2022) |
| "To identify the relationship between prophylactic indomethacin (PI) administration and (1) mortality and bronchopulmonary dysplasia (BPD) at 36-week postmenstrual age (PMA) (primary outcome), and (2) to evaluate for PI-associated acute kidney injury." | 4.02 | Prophylactic Indomethacin in extremely preterm infants: association with death or BPD and observed early serum creatinine levels. ( Abdi, HH; Backes, CH; Ball, MK; Jadcherla, SR; Klebanoff, MA; Mohamed, TH; Slaughter, JL; Talavera-Barber, MM, 2021) |
| " Mortality, severe neurological injury, retinopathy, necrotizing enterocolitis, bronchopulmonary dysplasia, nosocomial infection, and patent ductus arteriosus ligation rates were compared between infants who received antenatal steroids, prophylactic indomethacin, and/or prophylactic phototherapy and those who did not." | 3.81 | Prophylactic Interventions in Neonatology: How Do They Fare in Real Life? ( Harrison, A; Lee, SK; Piedbouf, B; Rolnitsky, A; Shah, PS, 2015) |
| " Infants who had PDA and survived beyond 72 hours were included in multivariable logistic regression analyses that compared mortality or any severe neonatal morbidity (intraventricular hemorrhage grades ≥ 3, retinopathy of prematurity stages ≥ 3, bronchopulmonary dysplasia, or necrotizing enterocolitis stages ≥ 2) between treatment groups (conservative management, indomethacin only, surgical ligation only, or both indomethacin and ligation)." | 3.78 | Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. ( Allen, AC; Aziz, K; Lee, SK; Mirea, L; Ohlsson, A; Sankaran, K; Seshia, M; Shah, PS, 2012) |
| "Treatment of a patent ductus arteriosus with COX-inhibitors such as indomethacin and ibuprofen, increases the risk for bronchopulmonary dysplasia without reducing other complications or death." | 3.75 | [Patent ductus arteriosus in premature infants]. ( Bratlid, D; Farstad, T, 2009) |
| "Our objective was to determine the effect of chorioamnionitis on plasma prostaglandin E2 (PGE2) and thromboxane B2 (TxB2) during the first week in preterm infants." | 3.74 | Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants. ( Aranda, JV; Glibetic, M; Natarajan, G; Thomas, RL, 2008) |
| "To determine the risk of bronchopulmonary dysplasia (BPD) in subgroups of infants with and without patent ductus arteriosus (PDA) who were randomized to indomethacin prophylaxis or placebo, and to examine whether adverse drug effects on edema formation and oxygenation may explain why indomethacin prophylaxis does not reduce BPD." | 3.73 | Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). ( Davis, P; Fanaroff, A; Kirpalani, HM; Nwaesei, C; Roberts, RS; Schmidt, B; Vincer, M, 2006) |
| " Intravenous indomethacin was administered to 67 infants with successful closure in 91% of the patients and in 83% of those with birth weights less than 1,000 g." | 3.66 | Parenteral indomethacin for closure of the patent ductus arteriosus. Clinical experience with 67 preterm infants. ( Alexson, CG; Harris, JP; Longfield, L; Manning, JA; Merritt, TA, 1982) |
| "Eighty pregnant women threatened with preterm labor between 24 and 34 weeks of gestation were enrolled in the study." | 2.67 | Increased incidence of bronchopulmonary dysplasia after antenatal administration of indomethacin to prevent preterm labor. ( Eronen, M; Hallman, M; Kurki, T; Pesonen, E; Teramo, K; Ylikorkala, O, 1994) |
| "Prophylactic closure of the patent ductus arteriosus has been recommended as a means of decreasing the morbidity of the very low birth weight neonate." | 2.66 | The silent ductus: its precursors and its aftermath. ( Hammerman, C; Strates, E; Valaitis, S, 1986) |
| "The patency of the ductus arteriosus is very common in extremely premature infants." | 2.53 | Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes. ( Bancalari, E, 2016) |
| "Symptomatic patent ductus arteriosus (sPDA) is the most common heart abnormality in preterm infants." | 1.62 | High Dose Indomethacin for Patent Ductus Arteriosus Closure Increases Neonatal Morbidity. ( Atkinson, A; Berger, MR; Gerull, R; Nelle, M; Waldvogel, S; Wilbeaux, M, 2021) |
| "Spontaneous closure of patent ductus arteriosus (PDA) occurs frequently in very preterm infants and despite the lack of evidence for treatment benefits, treatment for PDA is common in neonatal medicine." | 1.46 | Patent Ductus Arteriosus Treatment in Very Preterm Infants: A European Population-Based Cohort Study (EPICE) on Variation and Outcomes. ( Bonet, M; Boyle, EM; Edstedt Bonamy, AK; Fenton, A; Gortner, L; Gudmundsdottir, A; Hasselager, AB; Maier, RF; Milligan, D; Norman, M; Toome, L; van Heijst, A; Van Reempts, P; Zeitlin, J, 2017) |
| "The optimal timing of pharmacological treatment for patent ductus arteriosus (PDA) in extremely preterm infants is unknown." | 1.42 | Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants. ( Bonamy, AK; Gudmundsdottir, A; Håkansson, S; Johansson, S; Källen, K; Norman, M, 2015) |
| "The aim of this study is to compare patent ductus arteriosus (PDA) management strategies and outcomes between the Neonatal Research Network of Japan (NRNJ) with proactive functional echocardiography and the Canadian Neonatal Network (CNN) with selective conventional echocardiography practice." | 1.42 | Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches. ( Fujimura, M; Isayama, T; Kusuda, S; Lee, SK; Mirea, L; Mori, R; Shah, PS, 2015) |
| "Indomethacin therapy was given if plasma NT-proBNP level was ≥10,180 pg/mL, the cut-off for predicting hemodynamic significant PDA (hsPDA)." | 1.37 | N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants. ( Chongkongkiat, P; Khositseth, A; Nuntnarumit, P, 2011) |
| "The indomethacin-treated infants had a lower incidence of NEC and IVH." | 1.29 | Is surgical ligation of a patent ductus arteriosus the preferred initial approach for the neonate with extremely low birth weight? ( Garcia-Prats, JA; Jaksic, T; Pokorny, WJ; Robie, DK; Waltrip, T, 1996) |
| "Indomethacin treatment may augment lung inflammation and fibrosis by increasing BAL elastase activity and fibronectin concentration." | 1.27 | Effects of dexamethasone and indomethacin on elastase, alpha 1-proteinase inhibitor, and fibronectin in bronchoalveolar lavage fluid from neonates. ( Gerdes, JS; Harris, MC; Polin, RA, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (11.32) | 18.7374 |
| 1990's | 9 (16.98) | 18.2507 |
| 2000's | 11 (20.75) | 29.6817 |
| 2010's | 22 (41.51) | 24.3611 |
| 2020's | 5 (9.43) | 2.80 |
| Authors | Studies |
|---|---|
| Chawla, S | 1 |
| Natarajan, G | 2 |
| Laptook, AR | 1 |
| Chowdhury, D | 1 |
| Bell, EF | 1 |
| Ambalavanan, N | 1 |
| Carlo, WA | 1 |
| Gantz, M | 1 |
| Das, A | 1 |
| Tapia, JL | 1 |
| Harmon, HM | 1 |
| Shankaran, S | 1 |
| Hundscheid, T | 2 |
| Onland, W | 2 |
| Kooi, EMW | 2 |
| Vijlbrief, DC | 2 |
| de Vries, WB | 2 |
| Dijkman, KP | 2 |
| van Kaam, AH | 2 |
| Villamor, E | 2 |
| Kroon, AA | 2 |
| Visser, R | 2 |
| Mulder-de Tollenaer, SM | 2 |
| De Bisschop, B | 2 |
| Dijk, PH | 2 |
| Avino, D | 2 |
| Hocq, C | 2 |
| Zecic, A | 2 |
| Meeus, M | 2 |
| de Baat, T | 2 |
| Derriks, F | 2 |
| Henriksen, TB | 2 |
| Kyng, KJ | 2 |
| Donders, R | 2 |
| Nuytemans, DHGM | 2 |
| Van Overmeire, B | 3 |
| Mulder, AL | 2 |
| de Boode, WP | 2 |
| Waldvogel, S | 1 |
| Atkinson, A | 1 |
| Wilbeaux, M | 1 |
| Nelle, M | 1 |
| Berger, MR | 1 |
| Gerull, R | 1 |
| Evans, P | 1 |
| O'Reilly, D | 1 |
| Flyer, JN | 1 |
| Soll, R | 1 |
| Mitra, S | 1 |
| Abdi, HH | 1 |
| Backes, CH | 1 |
| Ball, MK | 1 |
| Talavera-Barber, MM | 1 |
| Klebanoff, MA | 1 |
| Jadcherla, SR | 1 |
| Mohamed, TH | 1 |
| Slaughter, JL | 1 |
| Liebowitz, M | 1 |
| Clyman, RI | 2 |
| Reese, J | 1 |
| Shelton, EL | 1 |
| Slaughter, JC | 1 |
| McNamara, PJ | 1 |
| Bhombal, S | 1 |
| Benitz, WE | 1 |
| Nelin, TD | 1 |
| Pena, E | 1 |
| Giacomazzi, T | 1 |
| Lee, S | 1 |
| Logan, JW | 1 |
| Moallem, M | 1 |
| Bapat, R | 1 |
| Shepherd, EG | 1 |
| Nelin, LD | 1 |
| Jensen, EA | 2 |
| Foglia, EE | 1 |
| Schmidt, B | 4 |
| Chan, NM | 1 |
| Law, CW | 1 |
| Kwan, KF | 1 |
| Gudmundsdottir, A | 3 |
| Johansson, S | 2 |
| Håkansson, S | 2 |
| Norman, M | 3 |
| Källen, K | 2 |
| Bonamy, AK | 2 |
| Meyer, S | 1 |
| Isayama, T | 1 |
| Mirea, L | 2 |
| Mori, R | 1 |
| Kusuda, S | 1 |
| Fujimura, M | 1 |
| Lee, SK | 3 |
| Shah, PS | 3 |
| Olsson, KW | 1 |
| Sindelar, R | 1 |
| Rolnitsky, A | 1 |
| Piedbouf, B | 1 |
| Harrison, A | 1 |
| Haw, MP | 1 |
| Bancalari, E | 1 |
| Edstedt Bonamy, AK | 1 |
| Maier, RF | 1 |
| Toome, L | 1 |
| Zeitlin, J | 1 |
| Bonet, M | 1 |
| Fenton, A | 1 |
| Hasselager, AB | 1 |
| van Heijst, A | 1 |
| Gortner, L | 1 |
| Milligan, D | 1 |
| Van Reempts, P | 1 |
| Boyle, EM | 1 |
| Dysart, KC | 1 |
| Gantz, MG | 1 |
| Carper, B | 1 |
| Higgins, RD | 1 |
| Keszler, M | 1 |
| Laughon, MM | 1 |
| Poindexter, BB | 1 |
| Stoll, BJ | 1 |
| Walsh, MC | 1 |
| Sankar, MJ | 1 |
| Agarwal, R | 1 |
| Deorari, AK | 1 |
| Paul, VK | 1 |
| Glibetic, M | 1 |
| Thomas, RL | 1 |
| Aranda, JV | 1 |
| Bratlid, D | 1 |
| Farstad, T | 1 |
| Nuntnarumit, P | 1 |
| Chongkongkiat, P | 1 |
| Khositseth, A | 1 |
| Anabrees, J | 1 |
| Alfaleh, K | 1 |
| Alfaleh, KM | 1 |
| Al Luwaimi, E | 1 |
| Alkharfi, TM | 1 |
| Al-Alaiyan, SA | 1 |
| Saldeño, YP | 1 |
| Favareto, V | 1 |
| Mirpuri, J | 1 |
| Sankaran, K | 1 |
| Seshia, M | 1 |
| Ohlsson, A | 1 |
| Allen, AC | 1 |
| Aziz, K | 1 |
| Chiang, PJ | 1 |
| Hsu, JF | 1 |
| Tsai, MH | 1 |
| Lien, R | 1 |
| Chiang, MC | 1 |
| Huang, HR | 1 |
| Chiang, CC | 1 |
| Liang, HF | 1 |
| Chu, SM | 1 |
| Asztalos, EV | 1 |
| Roberts, RS | 2 |
| Robertson, CM | 1 |
| Sauve, RS | 1 |
| Whitfield, MF | 1 |
| Gordon, PV | 1 |
| Hasan, SU | 1 |
| Bose, CL | 1 |
| Laughon, M | 1 |
| Fanaroff, A | 1 |
| Davis, P | 1 |
| Kirpalani, HM | 1 |
| Nwaesei, C | 1 |
| Vincer, M | 1 |
| Peckham, GJ | 1 |
| Miettinen, OS | 1 |
| Ellison, RC | 1 |
| Kraybill, EN | 1 |
| Gersony, WM | 1 |
| Zierler, S | 1 |
| Nadas, AS | 1 |
| Merritt, TA | 2 |
| White, CL | 1 |
| Coen, RW | 1 |
| Friedman, WF | 1 |
| Gluck, L | 1 |
| Rosenberg, M | 1 |
| Harris, JP | 1 |
| Alexson, CG | 1 |
| Longfield, L | 1 |
| Manning, JA | 1 |
| Lemke, RP | 1 |
| Saedi, SA | 1 |
| Casiro, O | 1 |
| Savani, RC | 1 |
| Eronen, M | 1 |
| Pesonen, E | 1 |
| Kurki, T | 1 |
| Teramo, K | 1 |
| Ylikorkala, O | 1 |
| Hallman, M | 1 |
| Vilanova Juanola, JM | 2 |
| Figueras Aloy, J | 2 |
| Molina González, J | 2 |
| Botet Mussons, F | 1 |
| Jiménez González, R | 2 |
| Robie, DK | 1 |
| Waltrip, T | 1 |
| Garcia-Prats, JA | 1 |
| Pokorny, WJ | 1 |
| Jaksic, T | 1 |
| Slootmaekers, V | 1 |
| De Loor, J | 1 |
| Buytaert, P | 1 |
| Hagendorens, M | 1 |
| Sys, SU | 1 |
| Van Reempts, PJ | 1 |
| Narayanan, M | 1 |
| Schlueter, M | 1 |
| Gordon, P | 1 |
| Rutledge, J | 1 |
| Sawin, R | 1 |
| Thomas, S | 1 |
| Woodrum, D | 1 |
| Watterberg, KL | 1 |
| Scott, SM | 1 |
| Backstrom, C | 1 |
| Gifford, KL | 1 |
| Cook, KL | 1 |
| Adamska, E | 1 |
| Wadhawan, R | 1 |
| Rubin, LP | 1 |
| Steinberg, JD | 1 |
| Bambang Oetomo, S | 1 |
| Martijn, A | 1 |
| Gerdes, JS | 1 |
| Harris, MC | 1 |
| Polin, RA | 1 |
| Pongiglione, G | 1 |
| Marasini, M | 1 |
| Silvestri, G | 1 |
| Tuo, P | 1 |
| Ribaldone, D | 1 |
| Bertolini, A | 1 |
| Garello-Cantoni, L | 1 |
| Hammerman, C | 1 |
| Strates, E | 1 |
| Valaitis, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center, Randomized Non-inferiority Trial of Early Treatment Versus Expectative Management of Patent Ductus Arteriosus in Preterm Infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)[NCT02884219] | 273 participants (Actual) | Interventional | 2016-12-23 | Completed | |||
| Long Term Follow-up of the TREOCAPA (Prophylactic TREatment Of the duCtus Arteriosus in Preterm Infants by Acetaminophen) Study (TREOCAPA-LT)[NCT06064825] | 500 participants (Anticipated) | Observational | 2023-11-30 | Not yet recruiting | |||
| Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants[NCT00063063] | 80,000 participants (Anticipated) | Observational | 1987-01-31 | Recruiting | |||
| Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)[NCT00009646] | Phase 3 | 1,202 participants (Actual) | Interventional | 1993-11-30 | Completed | ||
| Lactoferrin Infant Feeding Trial - LIFT_Canada[NCT03367013] | Phase 3 | 453 participants (Actual) | Interventional | 2018-02-16 | Active, not recruiting | ||
| Enteral Supplementation With High-dose Docosahexaenoic Acid on the Risk for Bronchopulmonary Dysplasia in Very Preterm Infants: A Collaborative Study Protocol for an Individual Participant Data Meta-analysis[NCT05915806] | 1,801 participants (Actual) | Interventional | 2023-07-30 | Active, not recruiting | |||
| Clinical Research on the Predictive Effect of Neonatal Morbidities on the Poor Outcomes to Very Low Birth-weight and Extremely Low Birth-weight Infants[NCT03104946] | 834 participants (Actual) | Observational | 2013-09-01 | Completed | |||
| Follow-up Visit of High Risk Infants[NCT00009633] | 68,000 participants (Anticipated) | Observational | 1993-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for indomethacin and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Indomethacin for symptomatic patent ductus arteriosus in preterm infants.
Topics: Bias; Bronchopulmonary Dysplasia; Cause of Death; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pate | 2021 |
Association between prophylactic indomethacin and death or bronchopulmonary dysplasia: A systematic review and meta-analysis of observational studies.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Ductus Arteriosus, | 2018 |
Surgical Intervention in Preterm Neonates with Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Combined Modality Therapy; Cyclooxygenase Inhibitors; Ductus Arteriosus, | 2016 |
Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Hemodynamics; Humans; Ibuprofen; Indomethacin | 2016 |
Chronic lung disease in newborns.
Topics: Adrenal Cortex Hormones; Bronchopulmonary Dysplasia; Combined Modality Therapy; Diuretics; Drug Ther | 2008 |
Fluid restriction and prophylactic indomethacin versus prophylactic indomethacin alone for prevention of morbidity and mortality in extremely low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Fluid Therapy; Humans; Indometh | 2011 |
[Neurologic evolution of premature infants following assisted ventilation, with and without bronchopulmonary dysplasia].
Topics: Bronchopulmonary Dysplasia; Female; Humans; Indomethacin; Infant, Newborn; Male; Nervous System Dise | 1993 |
[Ibuprofen--a new application for pharmacological closure of patent ductus arteriosus in preterm infants. Preliminary report].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Clinical Trials as Topic; Ductu | 2000 |
[Pathogenic factors in bronchopulmonary dysplasia].
Topics: Birth Weight; Bronchopulmonary Dysplasia; Gestational Age; Humans; Iatrogenic Disease; Indomethacin; | 1991 |
5 trials available for indomethacin and Bronchopulmonary Dysplasia
39 other studies available for indomethacin and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Model for severe intracranial hemorrhage and role of early indomethacin in extreme preterm infants.
Topics: Bronchopulmonary Dysplasia; Child; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant; | 2022 |
High Dose Indomethacin for Patent Ductus Arteriosus Closure Increases Neonatal Morbidity.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arte | 2021 |
Prophylactic Indomethacin in extremely preterm infants: association with death or BPD and observed early serum creatinine levels.
Topics: Bronchopulmonary Dysplasia; Child; Creatinine; Humans; Indomethacin; Infant; Infant, Extremely Prema | 2021 |
Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes.
Topics: Bronchopulmonary Dysplasia; Cohort Studies; Conservative Treatment; Cyclooxygenase Inhibitors; Ductu | 2017 |
Prophylactic Indomethacin Revisited.
Topics: Bronchopulmonary Dysplasia; Humans; Indomethacin; Infant; Infant, Extremely Premature; Infant, Newbo | 2017 |
Prophylactic Indomethacin-Is It Time to Reconsider?
Topics: Bronchopulmonary Dysplasia; Conservative Treatment; Ductus Arteriosus, Patent; Humans; Indomethacin; | 2017 |
Outcomes following indomethacin prophylaxis in extremely preterm infants in an all-referral NICU.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Bronchopulmonary Dysplasia; Cerebral Intraven | 2017 |
Ibuprofen versus indomethacin treatment of patent ductus arteriosus: comparative effectiveness and complications.
Topics: Bronchopulmonary Dysplasia; Creatinine; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indome | 2014 |
Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants.
Topics: Bronchopulmonary Dysplasia; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Fe | 2015 |
The importance of echocardiography and an individual approach to patent ductus arteriosus treatment in extremely preterm infants.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
Adequate timely treatment of patent ductus arteriosus in extremely low birth weight infants: an ongoing challenge.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
Patent ductus arteriosus management and outcomes in Japan and Canada: comparison of proactive and selective approaches.
Topics: Bronchopulmonary Dysplasia; Canada; Cerebral Hemorrhage; Comorbidity; Cyclooxygenase Inhibitors; Duc | 2015 |
Future Benefits of Sequential Echocardiography: Unmasking the Indications for Treatment of Patent Ductus Arteriosus in Extremely Preterm Infants.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
Prophylactic Interventions in Neonatology: How Do They Fare in Real Life?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Canada; Cross Infection; Ductus | 2015 |
Patent Ductus Arteriosus Treatment in Very Preterm Infants: A European Population-Based Cohort Study (EPICE) on Variation and Outcomes.
Topics: Bronchopulmonary Dysplasia; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Eu | 2017 |
Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Female; Humans; In | 2017 |
Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Bronchopulmonary Dysplasia | 2008 |
[Patent ductus arteriosus in premature infants].
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Hemodynamics; Huma | 2009 |
N-terminal-pro-brain natriuretic peptide: a guide for early targeted indomethacin therapy for patent ductus arteriosus in preterm Infants.
Topics: Bronchopulmonary Dysplasia; Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indome | 2011 |
A decision aid for considering indomethacin prophylaxis vs. symptomatic treatment of PDA for extreme low birth weight infants.
Topics: Adult; Bronchopulmonary Dysplasia; Cardiovascular Agents; Decision Support Techniques; Ductus Arteri | 2011 |
Prolonged persistent patent ductus arteriosus: potential perdurable anomalies in premature infants.
Topics: Analysis of Variance; Bronchopulmonary Dysplasia; Cardiac Surgical Procedures; Case-Control Studies; | 2012 |
Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias.
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Comorbidity; Cyclooxygenase Inhibitors; Ductus Arte | 2012 |
The impact of patent ductus arteriosus in neonates with late onset sepsis: a retrospective matched-case control study.
Topics: Age Factors; Bronchopulmonary Dysplasia; Case-Control Studies; Databases, Factual; Ductus Arteriosus | 2012 |
Weighing statistical certainty against ethical, clinical, and biologic expediency: the contributions of the Watterberg trial tip the scales in the right direction.
Topics: Adrenal Insufficiency; Betamethasone; Bronchopulmonary Dysplasia; Dexamethasone; Drug Synergism; Dru | 2005 |
Inhaled nitric oxide.
Topics: Administration, Inhalation; Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Dev | 2005 |
Treatment to prevent patency of the ductus arteriosus: beneficial or harmful?
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethac | 2006 |
Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethac | 2006 |
Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethac | 2006 |
Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethac | 2006 |
Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethac | 2006 |
Preschool assessment of infants with a patent ductus arteriosus: comparison of ligation and indomethacin therapy.
Topics: Body Height; Body Weight; Bronchopulmonary Dysplasia; Child Development; Child, Preschool; Ductus Ar | 1982 |
Parenteral indomethacin for closure of the patent ductus arteriosus. Clinical experience with 67 preterm infants.
Topics: Age Factors; Birth Weight; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Arteriosus, Paten | 1982 |
Antenatal indomethacin therapy and bronchopulmonary dysplasia.
Topics: Bronchopulmonary Dysplasia; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Prenatal Care | 1995 |
Is surgical ligation of a patent ductus arteriosus the preferred initial approach for the neonate with extremely low birth weight?
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Cerebral Ventricles; Chemotherapy, Adjuvant; Cycloo | 1996 |
The addition of indomethacin to betamimetics for tocolysis: any benefit for the neonate?
Topics: Adrenergic beta-Agonists; Bronchopulmonary Dysplasia; Cohort Studies; Female; Fetal Membranes, Prema | 1998 |
Incidence and outcome of a 10-fold indomethacin overdose in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Art | 1999 |
Early postnatal dexamethasone increases the risk of focal small bowel perforation in extremely low birth weight infants.
Topics: Anti-Inflammatory Agents; Bronchopulmonary Dysplasia; Case-Control Studies; Dexamethasone; Female; H | 1999 |
Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus.
Topics: Adrenal Insufficiency; Bronchoalveolar Lavage Fluid; Bronchopulmonary Dysplasia; Chronic Disease; Du | 2000 |
Early versus late treatment of PDA with indomethacin.
Topics: Bronchopulmonary Dysplasia; Cardiovascular Agents; Ductus Arteriosus, Patent; High-Frequency Ventila | 2002 |
Asymmetrical pulmonary changes in premature infants with surgical closure of a persistent ductus arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Humans; Hyaline Membrane Disease; Indomethaci | 1990 |
Effects of dexamethasone and indomethacin on elastase, alpha 1-proteinase inhibitor, and fibronectin in bronchoalveolar lavage fluid from neonates.
Topics: Acute-Phase Proteins; alpha 1-Antitrypsin; Blood Proteins; Bronchoalveolar Lavage Fluid; Bronchopulm | 1988 |
Early treatment of patent ductus arteriosus in premature infants with severe respiratory distress syndrome.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus; Ductus Arteriosus, Patent; Echocardiography; Female; | 1988 |